Early initiation of rhythm control therapy was found to reduce cardiovascular outcomes in patients with early atrial fibrillation and cardiovascular conditions.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Adding multiproteomic biomarkers to a clinical risk model for the evaluation of patients with diabetes and a recent myocardial infarction may provide better risk assessment.
The incidence of stress cardiomyopathy has increased during the COVID-19 pandemic.
Women who had previously taken β-blockers for hypertension were found to be at increased risk for heart failure in new-onset coronary heart disease.
A decrease in the number of cardiac catheterization procedures performed during the COVID-19 pandemic was observed at 12 hospitals in the United States.
Individuals with CAD who have not experienced a recent CV event are generally considered to have stable CAD.
The risk for peripheral artery disease events was found to be associated with levels of lipoprotein(a) in patients with recent acute coronary syndrome.
The majority of patients with acute coronary syndrome treated with statins were found to have low-density lipoproteins-cholesterol levels above those recommended by current guidelines.
Aboriginal and Torres Strait Islander status may predict death in individuals with acute coronary syndrome.
